HepaTx, a biotechnology company focused on regenerative medicine, has announced an exciting collaboration with the Mayo Clinic to advance its innovative cell therapy technology into clinical trials.
This partnership, revealed on September 10, 2024, aims to offer new therapeutic approaches for liver diseases, initially targeting alcohol-related hepatitis.
The collaboration leverages Mayo Clinic’s clinical research infrastructure to fast-track the development of HepaTx’s adipose-derived stem cell technology. This cutting-edge therapy has the potential to transform the treatment landscape for both acute and chronic liver conditions, potentially benefiting millions of patients worldwide.
HepaTx CEO, Eric Schuur, expressed enthusiasm for the collaboration, emphasizing the Mayo Clinic’s expertise in liver disease and regenerative medicine as key factors in advancing the technology to the clinical stage efficiently.
By accelerating the transition to human trials, this partnership could significantly improve outcomes and the quality of life for liver disease patients, addressing a critical need in an underserved market.
As liver disease continues to impose a significant health burden globally, this collaboration represents a major step toward innovative treatments that could dramatically alter the future of liver disease management.
Visit HepaTx for more info.